HI
XLRN

HBK Investments’s Acceleron Pharma XLRN Stock Holding History

HBK Investments’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-19,184
Closed -$652K – 1068
2016
Q2 		$652K Buy
+19,184
New +$624K ﹤0.01% 675

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

HBK Investments's XLRN Position: Q3 2016 in Review

HBK Investments sold out of Acceleron Pharma (XLRN) in Q3 2016, closing a stake of 19,184 shares — an estimated $652K sold.

HBK Investments first reported a position in XLRN in Q2 2016 and held it in 1 quarter. The position peaked at $652K in Q2 2016. 138 funds tracked by Wall St. Rank hold XLRN as of Q3 2016.

  • HBK Investments reported no remaining Acceleron Pharma position as of Q3 2016 after selling out during the quarter.
  • HBK Investments sold 19,184 Acceleron Pharma shares in Q3 2016, an estimated $652K.
  • HBK Investments first reported a position in Acceleron Pharma in Q2 2016 and held it in 1 quarter.
  • HBK Investments's Acceleron Pharma position peaked at $652K in Q2 2016.
  • 138 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2016.

Based on HBK Investments's 13F filing for Q3 2016, filed 14 Nov 2016.